BACKGROUND: A multinational clinical trial compared the safety and efficacy of intranasal trivalent live attenuated influenza vaccine (LAIV) with intramuscular trivalent inactivated vaccine (TIV) in very young children prior to the 2004-5 influenza season [1]. Wheezing was noted more often in recipients of LAIV and laboratory-confirmed influenza infection was noted more often in recipients of TIV. We sought to determine whether epidemiologic or genetic factors were associated with these outcomes. METHODS: Atopy surveys and DNA collections were performed in trial participants at two United States sites, Nashville, TN and Boston, MA. DNA samples were genotyped on Illumina Infinium 610 or 660-Quad. Standard allelic tests of association were performed. RESULTS: At the Nashville and Boston sites, a total of 99 children completed the trial, 6 (1 TIV, 5 LAIV) developed medically attended wheezing within 42 days following vaccination, and 8 (5 TIV, 3 LAIV) developed laboratory-confirmed influenza during the season. Eighty-one surveys and 70 DNA samples were collected. Family history of asthma (p=0.001) was associated with wheezing after vaccination. Of 468,458 single nucleotide polymorphisms tested in the genome-wide association study (GWAS), none achieved genome-wide significance for either wheezing after vaccination or laboratory-confirmed influenza infection. CONCLUSIONS: Family history of asthma appears to be a risk factor for wheezing after influenza vaccination. Given the limitations of the sample size, our pilot study demonstrated the feasibility of performing a GWAS but was not able to determine genetic polymorphisms associated with wheezing after influenza immunization.
BACKGROUND: A multinational clinical trial compared the safety and efficacy of intranasal trivalent live attenuated influenza vaccine (LAIV) with intramuscular trivalent inactivated vaccine (TIV) in very young children prior to the 2004-5 influenza season [1]. Wheezing was noted more often in recipients of LAIV and laboratory-confirmed influenza infection was noted more often in recipients of TIV. We sought to determine whether epidemiologic or genetic factors were associated with these outcomes. METHODS: Atopy surveys and DNA collections were performed in trial participants at two United States sites, Nashville, TN and Boston, MA. DNA samples were genotyped on Illumina Infinium 610 or 660-Quad. Standard allelic tests of association were performed. RESULTS: At the Nashville and Boston sites, a total of 99 children completed the trial, 6 (1 TIV, 5 LAIV) developed medically attended wheezing within 42 days following vaccination, and 8 (5 TIV, 3 LAIV) developed laboratory-confirmed influenza during the season. Eighty-one surveys and 70 DNA samples were collected. Family history of asthma (p=0.001) was associated with wheezing after vaccination. Of 468,458 single nucleotide polymorphisms tested in the genome-wide association study (GWAS), none achieved genome-wide significance for either wheezing after vaccination or laboratory-confirmed influenza infection. CONCLUSIONS: Family history of asthma appears to be a risk factor for wheezing after influenza vaccination. Given the limitations of the sample size, our pilot study demonstrated the feasibility of performing a GWAS but was not able to determine genetic polymorphisms associated with wheezing after influenza immunization.
Authors: Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland Journal: J Infect Dis Date: 2005-01-14 Impact factor: 5.226
Authors: Inna G Ovsyannikova; V Shane Pankratz; Robert A Vierkant; Robert M Jacobson; Gregory A Poland Journal: J Infect Dis Date: 2006-01-27 Impact factor: 5.226
Authors: Inna G Ovsyannikova; Robert M Jacobson; Robert A Vierkant; Steven J Jacobsen; V Shane Pankratz; Gregory A Poland Journal: Hum Immunol Date: 2004-12 Impact factor: 2.850
Authors: Theresa W Guilbert; Wayne J Morgan; Robert S Zeiger; Leonard B Bacharier; Susan J Boehmer; Marzena Krawiec; Gary Larsen; Robert F Lemanske; Andrew Liu; David T Mauger; Chris Sorkness; Stanley J Szefler; Robert C Strunk; Lynn M Taussig; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: Elena Crestani; Stefano Guerra; Anne L Wright; Marilyn Halonen; Fernando D Martinez Journal: J Allergy Clin Immunol Date: 2004-02 Impact factor: 10.793
Authors: Stefano Guerra; Anne L Wright; Wayne J Morgan; Duane L Sherrill; Catharine J Holberg; Fernando D Martinez Journal: Am J Respir Crit Care Med Date: 2004-03-17 Impact factor: 21.405
Authors: P Pellegrino; F S Falvella; V Perrone; C Carnovale; T Brusadelli; M Pozzi; S Antoniazzi; S Cheli; C Perrotta; E Clementi; S Radice Journal: Pharmacogenomics J Date: 2014-10-07 Impact factor: 3.550